Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AVI BioPharma has bagged a new contract for the advanced development of the hemorrhagic fever virus therapeutic candidates, AVI-6002 and AVI-6003, for Ebola and Marburg viruses, from the US Department of Defense Chemical and Biological Defense Program through the US Army Space and Missile Defense Command.
Subscribe to our email newsletter
AVI-6002 and AVI-6003 are RNA-based therapeutic candidates from AVI’s anti-infective portfolio and use its proprietary PMOplus chemistry.
The current contract is funded as part of the Transformational Medical Technologies (TMT) program, which was focused to develop platform-based solutions countering biological threats.
Further, the contract is structured into four segments with potential funding of up to approximately $291m. Activity under the first segment is to begin immediately and provides for funding to the company of up to approximately $80m.
After completion of the first segment, and each successive segment, TMT has the option to proceed to the next segment for either or both AVI-6002 and AVI-6003.
If TMT exercises its options for all four segments, contract activities would include all clinical and licensure activities necessary to obtain FDA regulatory approval of each therapeutic candidate and would provide for a total funding award to the AVI of up to approximately $291m.